Corvus Pharmaceuticals (CRVS) Stock Soars 211.8% to New All-Time High
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2d ago
0mins
Source: Yahoo Finance
- Clinical Trial Success: Corvus Pharmaceuticals' drug candidate demonstrated a 72% reduction in eczema severity in the first phase trial, significantly outperforming the 40% reduction seen in the placebo group, indicating its potential for treating moderate to severe eczema patients.
- Stock Surge: Last week, Corvus Pharmaceuticals' stock soared by 211.8%, reaching an all-time high of $26.95 on Friday, although it closed down 1.65% at $25.10, reflecting strong market enthusiasm for its clinical results.
- Follow-Up Trial Plans: The company plans to initiate a Phase 2 trial in Q1 2026, targeting 200 patients with moderate-to-severe atopic dermatitis, further validating the efficacy of soquelitinib and demonstrating its ongoing market development potential.
- Trial Design Details: The Phase 2 trial will consist of four cohorts of 50 patients each, testing different doses of soquelitinib over a 12-week period with a 30-day follow-up, aimed at providing robust clinical data to support future treatment options.
Analyst Views on CRVS
Wall Street analysts forecast CRVS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRVS is 13.33 USD with a low forecast of 11.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 23.010
Low
11.00
Averages
13.33
High
16.00
Current: 23.010
Low
11.00
Averages
13.33
High
16.00
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
